NOVO NORDISK A S Form 6-K February 03, 2015 UNITED STATES

#### SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 6-K

#### REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

February 2, 2015

NOVO NORDISK A/S (Exact name of Registrant as specified in its charter)

> Novo Allé DK- 2880, Bagsvaerd Denmark (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X] Form 40-F [ ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [ ] No [X]

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_

Trading in Novo Nordisk shares by board members, executives and associated persons on 30 January 2015

Bagsværd, Denmark, 2 February 2015 - In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.

As from 2004, members of Novo Nordisk's Executive Management and other members of the Senior Management Board have participated in a long-term share-based incentive programme where a proportion of the calculated shareholder value creation has been allocated to a joint pool for the participants. For 2011, 448,560 shares were allocated to the joint pool and the market value of the scheme was expensed in the accounts for 2011. In accordance with the principles of the programme, the Board of Directors of Novo Nordisk A/S on 29 January 2015 evaluated that the conditions for release of the joint pool of shares have been fulfilled.

Accordingly, the shares in the joint pool were transferred to 31 current and former members of senior management on 30 January 2015.

As of 2007, a number of key employees below senior management also participate in a share-based programme with similar performance criteria as the programme for senior management. A programme was established for 2011, and in line with the programme for senior management, the Board of Directors of Novo Nordisk A/S on 29 January 2015 evaluated that the conditions for release of the shares have been fulfilled and the shares were transferred to the participants on 30 January 2015 accordingly. An employee- elected member of the Board of Directors has participated in this programme and the reporting below reflects this participation.

Name Reason for reporting

Financial instrument and ID code Type of transaction

Date of transaction Place of transaction Volume of transaction Total value of transaction Liselotte Hyveled Member of the Board of Directors (employee representative) Novo Nordisk B DK0060534915 Other transaction (transfer of shares in accordance with long-term incentive programme) 30 January 2015 Nasdaq Copenhagen 2,030 shares 0 (transferred in accordance with the long-term incentive programme for 2011)

Name Reason for reporting	Liselotte Hyveled Member of the Board of Directors (employee representative)
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Sale of shares
Date of transaction	30 January 2015
Place of transaction	Nasdaq Copenhagen

677 shares

DKK 200,054

Page 2 of 11

Volume of transaction

Total value of transaction

Name Reason for reporting Financial instrument and ID code Type of transaction

Date of transaction Place of transaction Volume of transaction Total value of transaction

Name Reason for reporting Financial instrument and ID code Type of transaction

Date of transaction Place of transaction Volume of transaction Total value of transaction Lars Rebien Sørensen Chief Executive Officer Novo Nordisk B DK0060534915 Other transaction (transfer of shares in accordance with long-term incentive programme) 30 January 2015 Nasdaq Copenhagen 37,515 shares 0 (transferred in accordance with the long-term incentive programme for 2011)

Kåre Schultz President and Chief Operating Officer Novo Nordisk B DK0060534915 Other transaction (transfer of shares in accordance with long-term incentive programme) 30 January 2015 Nasdaq Copenhagen 25,010 shares 0 (transferred in accordance with the long-term incentive programme for 2011)

Page 3 of 11

Name Reason for reporting Financial instrument and ID code Type of transaction Date of transaction Place of transaction Volume of transaction Total value of transaction

Name Reason for reporting Financial instrument and ID code Type of transaction

Date of transaction Place of transaction Volume of transaction Total value of transaction

Page 4 of 11

Kåre Schultz President and Chief Operating Officer Novo Nordisk B DK0060534915 Sale of shares 30 January 2015 Nasdaq Copenhagen 10,010 shares DKK 2,990,668

Jesper Brandgaard Chief Financial Officer Novo Nordisk B DK0060534915 Other transaction (transfer of shares in accordance with long-term incentive programme) 30 January 2015 Nasdaq Copenhagen 25,010 shares 0 (transferred in accordance with the long-term incentive programme for 2011)

Name Reason for reporting Financial instrument and ID code Type of transaction Date of transaction Place of transaction Volume of transaction Total value of transaction

Name Reason for reporting Financial instrument and ID code Type of transaction

Date of transaction Place of transaction Volume of transaction Total value of transaction

Page 5 of 11

Jesper Brandgaard Chief Financial Officer Novo Nordisk B DK0060534915 Sale of shares 30 January 2015 Nasdaq Copenhagen 25,010 shares DKK 7,474,239

Lars Fruergaard Jørgensen Chief of Staff Novo Nordisk B DK0060534915 Other transaction (transfer of shares in accordance with long-term incentive programme) 30 January 2015 Nasdaq Copenhagen 12,505 shares 0 (transferred in accordance with the long-term incentive programme for 2011)

Name Reason for reporting Financial instrument and ID code Type of transaction Date of transaction Place of transaction Volume of transaction Total value of transaction	Lars Fruergaard Jørgensen Chief of Staff Novo Nordisk B DK0060534915 Sale of shares 30 January 2015 Nasdaq Copenhagen 7,000 shares DKK 2,091,950
Name Reason for reporting Financial instrument and ID code Type of transaction	Jakob Riis Executive Vice President Novo Nordisk B DK0060534915 Other transaction (transfer of shares in accordance with long-term incentive programme)
Date of transaction Place of transaction Volume of transaction Total value of transaction	30 January 2015 Nasdaq Copenhagen 12,505 shares 0 (transferred in accordance with the long-term incentive programme for 2011)

Page 6 of 11

Name Reason for reporting Financial instrument and ID code Type of transaction

Date of transaction Place of transaction Volume of transaction Total value of transaction Mads Krogsgaard Thomsen Chief Science Officer Novo Nordisk B DK0060534915 Other transaction (transfer of shares in accordance with long-term incentive programme) 30 January 2015 Nasdaq Copenhagen 25,010 shares 0 (transferred in accordance with the long-term incentive programme for 2011)

Name Reason for reporting Financial instrument and ID code Type of transaction Date of transaction Place of transaction Volume of transaction Total value of transaction

Page 7 of 11

Mads Krogsgaard Thomsen Chief Science Officer Novo Nordisk B DK0060534915 Sale of shares 30 January 2015 Nasdaq Copenhagen 23,190 shares DKK 6,930,332

Name Reason for reporting Financial instrument and ID code Type of transaction Date of transaction Place of transaction Volume of transaction Total value of transaction Mads Krogsgaard Thomsen Chief Science Officer Novo Nordisk B DK0060534915 Transfer of shares to pension account 30 January 2015 Nasdaq Copenhagen 1,820 shares DKK 543,907

Page 8 of 11

Below please find other trading in shares issued by Novo Nordisk.

Name Reason for reporting Financial instrument and ID code Type of transaction Date of transaction Place of transaction Volume of transaction Total value of transaction	Mads Krogsgaard Thomsen Chief Science Officer Novo Nordisk B DK0060534915 Donation of shares (gift) 30 January 2015 Nasdaq Copenhagen 600 shares DKK 180,870
Name Reason for reporting	Sebastian Krogsgaard Gudnason Associated to a member of Executive Management, Mads Krogsgaard
Financial instrument and ID code Type of transaction Date of transaction Place of transaction Volume of transaction Total value of transaction	Thomsen Novo Nordisk B DK0060534915 Receipt of shares (gift) 30 January 2015 Nasdaq Copenhagen 200 shares DKK 60,290

Page 9 of 11

Name Reason for reporting

Financial instrument and ID code Type of transaction Date of transaction Place of transaction Volume of transaction Total value of transaction Signe Krogsgaard Gudnason Associated to a member of Executive Management, Mads Krogsgaard Thomsen Novo Nordisk B DK0060534915 Receipt of shares (gift) 30 January 2015 Nasdaq Copenhagen 200 shares DKK 60,290

Definitions and background information:

Publication

Publication shall take place no later than two working days after the trading by board members or executives or notification of trading by associated persons. Publication is only required when the total amount of transactions of a specific board member/executive and his/her associated persons in any one calendar year has reached 5,000 euros.

Who are board members, executives and associated persons?

Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) relatives defined as brothers, sisters, parents, grandparents etc, children, grandchildren etc who have shared the same household with a board member/executive for at least one year, and 4) any legal person, including a company, a foundation or a partnership, which is controlled directly or indirectly by a board member/executive and/or a person mentioned in 1)–3), or to which a board member/executive and/or a person mentioned in 1)–3) has managerial responsibilities or economic interests substantially equivalent to the legal person.

What is trading/transaction?

Trading is any kind of transaction, including shares purchased or otherwise acquired, shares sold or otherwise disposed, gifts, mortgages and grants and exercise of options, but not heritage.

Page 10 of 11